JP2023551027A5 - - Google Patents

Info

Publication number
JP2023551027A5
JP2023551027A5 JP2023532547A JP2023532547A JP2023551027A5 JP 2023551027 A5 JP2023551027 A5 JP 2023551027A5 JP 2023532547 A JP2023532547 A JP 2023532547A JP 2023532547 A JP2023532547 A JP 2023532547A JP 2023551027 A5 JP2023551027 A5 JP 2023551027A5
Authority
JP
Japan
Application number
JP2023532547A
Other languages
Japanese (ja)
Other versions
JPWO2022111425A5 (https=
JP2023551027A (ja
Filing date
Publication date
Priority claimed from CN202011332200.9A external-priority patent/CN112480248B/zh
Application filed filed Critical
Publication of JP2023551027A publication Critical patent/JP2023551027A/ja
Publication of JP2023551027A5 publication Critical patent/JP2023551027A5/ja
Publication of JPWO2022111425A5 publication Critical patent/JPWO2022111425A5/ja
Pending legal-status Critical Current

Links

JP2023532547A 2020-11-24 2021-11-23 Cldn18.2に特異的に結合する分子 Pending JP2023551027A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011332200.9A CN112480248B (zh) 2020-11-24 2020-11-24 与cld18a2特异性结合的分子
CN202011332200.9 2020-11-24
PCT/CN2021/132218 WO2022111425A1 (zh) 2020-11-24 2021-11-23 与cldn18.2特异性结合的分子

Publications (3)

Publication Number Publication Date
JP2023551027A JP2023551027A (ja) 2023-12-06
JP2023551027A5 true JP2023551027A5 (https=) 2024-01-11
JPWO2022111425A5 JPWO2022111425A5 (https=) 2024-01-11

Family

ID=74934321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532547A Pending JP2023551027A (ja) 2020-11-24 2021-11-23 Cldn18.2に特異的に結合する分子

Country Status (7)

Country Link
US (1) US20240092891A1 (https=)
EP (1) EP4253411A4 (https=)
JP (1) JP2023551027A (https=)
CN (2) CN112480248B (https=)
AU (1) AU2021387558A1 (https=)
CA (1) CA3200052A1 (https=)
WO (1) WO2022111425A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
JP7781174B2 (ja) * 2021-05-31 2025-12-05 シージャツァング イーリング ファーマシューティカル カンパニー リミテッド CLDN18.2に対するモノクローナル抗体及びそのFc操作されたバージョン
CN115611983A (zh) 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
CR20240124A (es) * 2021-08-09 2024-08-06 Harbour Biomed Shanghai Co Ltd Anticuerpo dirigido contra cldn18.2, anticuerpo biespecífico y el uso de estos
CN118215686A (zh) * 2021-08-27 2024-06-18 三优生物医药(上海)有限公司 靶向pd-l1和cldn18.2的双特异性抗体及其制备方法和应用
CN115991784A (zh) 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体及其用途
CN118139888A (zh) * 2021-11-05 2024-06-04 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
EP4642489A1 (en) * 2022-12-26 2025-11-05 Full-Life Technologies HK Limited Conjugate and uses thereof
AU2024282453A1 (en) * 2023-05-31 2025-12-04 Full-Life Technologies Uk Limited Conjugates and uses thereof
CN117327182B (zh) * 2023-09-19 2024-06-04 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用
CN117304323A (zh) * 2023-09-28 2023-12-29 南京蓬勃生物科技有限公司 结合Claudin 18.2的结合部分及其应用
WO2026076388A1 (en) * 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH591382A5 (https=) 1974-05-28 1977-09-15 Ferag Ag
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
SI2852408T1 (sl) * 2012-05-23 2017-10-30 Ganymed Pharmaceuticals Gmbh Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
JP7398380B2 (ja) * 2018-03-08 2023-12-14 フェインズ セラピューティクス,インコーポレーテッド 抗クローディン18.2抗体及びその使用
SG11202007074PA (en) * 2018-05-18 2020-08-28 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
CN111867630B (zh) * 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
CN111848809A (zh) * 2019-04-08 2020-10-30 上海健信生物医药科技有限公司 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
CN111518214B (zh) * 2019-02-03 2023-09-22 上海健信生物医药科技有限公司 靶向cldn18.2的双特异性抗体及其制备方法和应用
JOP20210022A1 (ar) * 2018-08-03 2021-01-28 Amgen Inc بنيات جسم مضاد لـ cldn18.2وcd3
CN114106183B (zh) * 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020238730A1 (zh) * 2019-05-24 2020-12-03 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
TW202229335A (zh) * 2020-10-12 2022-08-01 美商健生生物科技公司 用於多方向性生物輸送之生物合成材料及方法
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2023551027A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)